Recombinant Human Siglec-9 protein (His Tag)
种属
Human
纯度
>90 %, SDS-PAGE
标签
His Tag
生物活性
未测试
验证数据展示
产品信息
纯度 | >90 %, SDS-PAGE |
内毒素 | <0.1 EU/μg protein, LAL method |
生物活性 | Not tested |
来源 | HEK293-derived Human Siglec-9 protein Gln18-Gly348 (Accession# Q9Y336-1) with a His tag at the C-terminus. |
基因ID | 27180 |
蛋白编号 | Q9Y336-1 |
预测分子量 | 40.1 kDa |
SDS-PAGE | 48-70 kDa, reducing (R) conditions |
组分 | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
复溶 | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
储存条件 |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
运输条件 | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
背景信息
Sialic acid binding Ig-like lectin 9 (Siglec-9), also known as CD329, is a member of the Siglec family of glycan-recognition proteins. Siglec-9 is a type-I transmembrane protein consisting of an N-terminal extracellular region that contains an N-terminal V-set domain and two C2-set domains, a transmembrane region, and an intracellular domain with an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an ITIM-like motif. It is expressed quite broadly among human blood leukocytes, including monocytes, neutrophils, B cells, NK cells, and minor subsets of T cells. Siglec-9 functions as an inhibitory immune checkpoint and can be targeted to enhance therapeutic antitumor immunity.
参考文献:
1. Zhang JQ. et al. (2000). J Biol Chem. 275(29):22121-6. 2. Zheng Y. et al. (2020). J Immunol Res. 2020:6243819. 3. Ibarlucea-Benitez I. et al. (2021). Proc Natl Acad Sci U S A. 118(26):e2107424118. 4. Mei Y. et al. (2023). Nat Cancer. 4(9):1273-1291.